Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 (liposomal tacrolimus oral rinse) for the treatment of Oral Lichen Planus (OLP) will be presented at the 2025 joint international meeting of the American Academy of Oral Me

Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven U.S. study sites. Topline results from the final cohort (1.0 mg) remain on track for the second quarter of 2025 and will represent the most

PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Michael Pietrack. The episode, titled "From Medicine to Biotech Innovation," offers an inside look at Dr. Chancellor's journey from clinical medicine to biotech leadership. In this candid conversation, he discusses how Lipella's innovation was born out of unmet medical

New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries. Spartan Capital successfully served as the sole placement agent for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) in a $3.788 million private placement. This financing represents an important milestone in Lipella's efforts to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman. The firm also played a key role as Co-Place

New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in this private offering. The proceeds from this offering will further Lipella's mission to develop innovative therapies addressing significant unmet medical needs, while also funding general corporate purposes. Jonathan Kaufman, PhD, CEO of Lipella Pharmaceuticals, remains committed to leading the company's groundbreaking clinical pipeline and advancing transformative treatment

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today shar

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain,

New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) --  Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions. The private placements were successfully completed, subject to customary closing conditions. The proceeds from these offerings will support Lipella's continued advancement of its clinical pipeline and general corpor

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

424B5 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

424B3 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

EFFECT - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

D - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)